Montelukast Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in both adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms. - Asthma: improves long‑term control and reduces the frequency of asthma attacks. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain: occasional discomfort. - Cough: non‑productive. - Diarrhoea: mild episodes. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Mood changes: including depression or suicidal thoughts. - Allergic reactions: such as angio‑edema or anaphylaxis. - Hepatotoxicity: elevated liver enzymes. - Stevens‑Johnson syndrome: severe skin eruption. - Churg‑Strauss syndrome: rare vasculitis. - Severe bronchospasm: paradoxical worsening of breathing.

Before prescribing Montelukast, consider the following safety measures. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Breastfeeding: assess infant exposure; monitor for adverse effects. - Hepatic impairment: use with caution; monitor liver function. - Neuropsychiatric symptoms: observe for mood changes or suicidal ideation. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: can lower therapeutic levels of montelukast.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs): may increase risk of neuropsychiatric events. - Warfarin: occasional reports of altered INR; monitor coagulation. - CYP3A4 inhibitors (e.g., ketoconazole): may modestly raise montelukast exposure. - CYP2C9 inhibitors (e.g., fluconazole): potential increase in drug levels. - Herbal supplements (e.g., St. John’s wort): may induce metabolism, reducing efficacy.